The DOI matches its Crossref record, with a small difference in title or year; 35 of the 35 references it cites were found in a registry or an index.
Microglial activation correlates with severity in Huntington disease: A clinical and PET study
Abstract
BACKGROUND: Huntington disease (HD) is characterized by the progressive death of medium spiny dopamine receptor bearing striatal GABAergic neurons. In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process. METHODS: To evaluate in vivo the involvement of microglia activation in HD, the authors studied patients at different stages of the disease using [(11)C](R)-PK11195 PET, a marker of microglia activation, and [(11)C]raclopride PET, a marker of dopamine D2 receptor binding and hence striatal GABAergic cell function. RESULTS: In HD patients, a significant increase in striatal [(11)C](R)-PK11195 binding was observed, which significantly correlated with disease severity as reflected by the striatal reduction in [(11)C]raclopride binding, the Unified Huntington's Disease Rating Scale score, and the patients' CAG index. Also detected were significant increases in microglia activation in cortical regions including prefrontal cortex and anterior cingulate. CONCLUSIONS: These [(11)C](R)-PK11195 PET findings show that the level of microglial activation correlates with Huntington disease (HD) severity. They lend support to the view that microglia contribute to the ongoing neuronal degeneration in HD and indicate that [(11)C](R)-PK11195 PET provides a valuable marker when monitoring the efficacy of putative neuroprotecting agents in this relentlessly progressive genetic disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Huntington's disease is associated with a reactive microglial response and consequent inflammation.”
From Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease (2020) · cites this paper as Pavese et al., 2006
In the citing paper
“In Huntington's disease, microglial activation is detected years before the onset of clinical symptoms and correlates with striatal neuron dysfunction in subclinical (Tai et al. , 2007) as well as clinical stages of the disease (Pavese et al. , 2006; Politis et al. , 2011).”
From Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease (2020) · cites this paper as Pavese et al., 2006
Citations
Cites
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Unified Huntington's disease rating scale: Reliability and consistency
Kremer, H. P. H. (1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,149
Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model
Gunn, R. N., Lammertsma, A. A., Hume, S. P., & Cunningham, V. J. (1997) · NeuroImage · doi:10.1006/nimg.1997.0303 · Cited by 1,085
Unified Huntington's disease rating scale: reliability and consistency
Kremer, H. P. H. (1996) · Radboud Repository (Radboud University) · Cited by 1,059
Microglia as neuroprotective, immunocompetent cells of the CNS
Streit, W. J. (2002) · Glia · doi:10.1002/glia.10154 · Cited by 919
Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
Piccini, P. P., Brooks, D. J., Björklund, A., Gunn, R. N., Grasby, P. M., Rimoldi, O. E., Brundin, P., Hagell, P., Rehncrona, S., Widner, H., et al. (1999) · Nature Neuroscience · doi:10.1038/16060 · Cited by 700
Self-citationMicroglia in health and disease
Kim, S. U., & de Vellis, J. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20562 · Cited by 687
CAG repeat number governs the development rate of pathology in Huntington's disease
Penney, J. B., Vonsattel, J., MacDonald, M. E., Gusella, J. F., & Myers, R. H. (1997) · Annals of Neurology · doi:10.1002/ana.410410521 · Cited by 670
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Self-citationEarly and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain
Sapp, E., Kegel, K. B., D, N. A. M., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P. G., Vonsattel, J., & DiFiglia, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.2.161 · Cited by 558
Kuhl, D. E., Phelps, M. E., Markham, C. H., Metter, E. J., Riege, W. H., & Winter, J. (1982) · Annals of Neurology · doi:10.1002/ana.410120504 · Cited by 376
Orexin loss in Huntington's disease
Petersén, Å., Gil‐Mohapel, J., Maat–Schieman, M. L. C., Björkqvist, M., Tanila, H., Araújo, I. M., Smith, R. A., Popović, N., Wierup, N., Norlén, P., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddi004 · Cited by 269
[ 11 C]( R )-PK11195 PET imaging of microglial activation in multiple system atrophy
Gerhard, A., Banati, R. B., Goerres, G. B., Cagnin, A., Myers, R., Gunn, R. N., Turkheimer, F., Good, C. D., Mathias, C. J., Quinn, N. P., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000078192.95645.e6 · Cited by 247
Self-citationGinovart, N. (1997) · Brain · doi:10.1093/brain/120.3.503 · Cited by 241
Young, A. B., Penney, J. B., Starosta‐Rubinstein, S., Markel, D. S., Berent, S., Giordani, B., Ehrenkaufer, R., Jewett, D., & Hichwa, R. (1986) · Annals of Neurology · doi:10.1002/ana.410200305 · Cited by 218
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study
Pavese, N., Andrews, T., Brooks, D. J., Ho, A. K., Rosser, A., Barker, R., Robbins, T. W., Sahakian, B. J., Dunnett, S. B., & Piccini, P. P. (2003) · Brain · doi:10.1093/brain/awg119 · Cited by 207
Self-citationBasal Ganglia Volume and Proximity to Onset in Presymptomatic Huntington Disease
Aylward, E., Codori, A., Barta, P. E., Pearlson, G. D., Harris, G. J., & Brandt, J. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550120105023 · Cited by 188
Cortical and striatal neurone number in Huntington's disease
Heinsen, H., Strik, M., Bauer, M., Luther, K., Ulmar, G., Gangnus, D., Jungkunz, G., Eisenmengers, W., & G�tz, M. (1994) · Acta Neuropathologica · doi:10.1007/bf00310376 · Cited by 175
Huntington's disease progression
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H. A., Sahakian, B., Hodges, J. R., Rosser, A. E., Wood, N. W., & Brooks, D. J. (1999) · Brain · doi:10.1093/brain/122.12.2353 · Cited by 169
Self-citationTurjanski, N., Weeks, R., Dolan, R. J., Harding, A. E., & Brooks, D. J. (1995) · Brain · doi:10.1093/brain/118.3.689 · Cited by 159
Self-citationMicroglial Functions and Proteases
Nakanishi, H. (2003) · Molecular Neurobiology · doi:10.1385/mn:27:2:163 · Cited by 158
Physical characteristics of the ECAT EXACT3D positron tomograph
Spinks, T. J., Jones, T., Bloomfield, P. M., Bailey, D. L., Miller, M., Hogg, D., Jones, W. F., Vaigneur, K., Reed, J. L., Young, J., et al. (2000) · Physics in Medicine and Biology · doi:10.1088/0031-9155/45/9/313 · Cited by 155
Antonini, A., Leenders, K. L., & Eidelberg, D. (1998) · Annals of Neurology · doi:10.1002/ana.410430216 · Cited by 127
Minocycline in Huntington's disease: A pilot study
Thomas, M., Ashizawa, T., & Jankovic, J. J. (2004) · Movement Disorders · doi:10.1002/mds.20018 · Cited by 111
Scherfler, C. (2004) · Brain · doi:10.1093/brain/awh150 · Cited by 108
Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study
Goerendt, I. K. (2003) · Brain · doi:10.1093/brain/awg035 · Cited by 100
Wilms, H. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.08.042 · Cited by 100
Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease
Meßmer, K., & Reynolds, G. P. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00967-1 · Cited by 89
Prefrontal cortical blood flow and cognitive function in Huntington's disease.
Weinberger, D. R., Berman, K. F., Iadarola, M. J., Driesen, N. R., & Zec, R. F. (1988) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.1.94 · Cited by 87
Minocycline for Huntington’s disease: An open label study
Bonelli, R. M., Heuberger, C., & Reisecker, F. (2003) · Neurology · doi:10.1212/01.wnl.0000049936.85487.7a · Cited by 86
Minocycline safety and tolerability in Huntington disease
Huntington Study Group (2004) · Neurology · doi:10.1212/01.wnl.0000133403.30559.ff · Cited by 76
Sax, D. S., Powsner, R. A., Kim, A., Tilak, S., Bhatia, R. G., Cupples, L. A., & Myers, R. H. (1996) · Movement Disorders · doi:10.1002/mds.870110612 · Cited by 61
Melton, L., Keith, A. B., Davis, S., Oakley, A. E., Edwardson, J. A., & Morris, C. M. (2003) · Glia · doi:10.1002/glia.10276 · Cited by 58
Cerebral Blood Flow and Cognitive Testing Correlate in Huntington's Disease
Tanahashi, N., Meyer, J. S., Ishikawa, Y., Kandula, P., Mortel, K. F., Rogers, R. L., Gandhi, S., & Walker, M. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060110051015 · Cited by 35
Research works printed but not linked: 1
- Talairach J Tournoux P.A coplanar sterotactic atlas of the human brain. New York: Thieme 1988.
Cited by
Sorted by citations
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,816
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710
Rupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N., Groyer, G., Adams, D., & Schumacher, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3295 · Cited by 930
Does neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
“Once symptoms have manifested, microglial activation correlates with disease severity [115,116].”
Metadata
- Authors
- Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- Neurology
- Published
- 2006-06-13
- Volume
- 66
- Issue
- 11
- Pages
- 1638-1643
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2025681964
- Cited by
- 462
- References
- 35
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 30 · 2023: 26 · 2022: 22 · 2021: 26 · 2020: 27 · 2019: 19 · 2018: 18 · 2017: 31 · 2016: 25 · 2015: 25 · 2014: 38 · 2013: 19 · 2012: 14
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Huntington's disease, microglial activation, dopamine D2 receptor binding, disease severity, neuroinflammation, neurodegeneration, prefrontal cortex, anterior cingulate cortex, CAG repeat expansion
- MeSH terms
- Adult, Aged, Amides, Corpus Striatum, Female, Humans, Huntington Disease, Isoquinolines, Male, Middle Aged, Sensitivity and Specificity, Severity of Illness Index, Statistics as Topic, Reproducibility of Results, Microglia, Radiopharmaceuticals, Raclopride, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
